RESUMO
Autoimmune neuropathies are named by eponyms, by descriptive terminology or because of the presence of specific antibodies and are traditionally classified, on the basis of pathology and electrophysiology, as primary demyelinating or axonal. However, autoimmune disorders targeting specific molecules of the nodal region, although not showing pathological evidence of demyelination, can exhibit all the electrophysiological changes considered characteristic of a demyelinating neuropathy and acute neuropathies with antiganglioside antibodies, classified as axonal and due to nodal dysfunction, can present with reversible conduction failure and prompt recovery that appear contradictory with the common view of an axonal neuropathy. These observations bring into question the concepts of demyelinating and axonal nerve conduction changes and the groundwork of the classical dichotomous classification.We propose a classification of autoimmune neuropathies based on the involved domains of the myelinated fibre and, when known, on the antigen. This classification, in our opinion, helps to better systematise autoimmune neuropathies because points to the site and molecular target of the autoimmune attack, reconciles some contrasting pathological and electrophysiological findings, circumvents the apparent paradox that neuropathies labelled as axonal may be promptly reversible and finally avoids taxonomic confusion and possible misdiagnosis.
Assuntos
Doenças Autoimunes do Sistema Nervoso/classificação , Bainha de Mielina/patologia , Antígenos , Autoanticorpos , Axônios/patologia , Humanos , Condução NervosaRESUMO
BACKGROUND: To investigate age-related severity, patterns of retinal structural damage, and functional visual recovery in pediatric and adult cohorts of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) optic neuritis (ON). METHODS: All MOGAD patients from the 5 participating centers were included. Patients with initial manifestation <18 years were included in the pediatric (MOGADped) cohort and patients with ≥18 years in the adult (MOGADadult) cohort. For patients with MOGAD ON, examinations at least ≥6 months after ON onset were included in the analyses. Using spectral domain optical coherence tomography (SD-OCT), we acquired peripapillary retinal nerve fiber layer thickness (pRNFL) and volumes of combined ganglion cell and inner plexiform layer (GCIPL). High- and 2.5% low-contrast visual acuity (HCVA, LCVA) and visual-evoked potentials (VEP) were obtained. RESULTS: Twenty MOGADped (10.3±3.7 years, 30 MOGAD ON eyes) and 39 MOGADadult (34.9±11.6 years, 42 MOGAD ON eyes) patients were included. The average number of ON episodes per ON eye was similar in both groups (1.8±1.3 and 2.0±1.7). In both pediatric and adult MOGAD, ON led to pronounced neuroaxonal retinal atrophy (pRNFL: 63.1±18.7 and 64.3±22.9 µm; GCIPL: 0.42±0.09 and 0.44±0.13 mm3, respectively) and moderate delay of the VEP latencies (117.9±10.7 and 118.0±14.5 ms). In contrast, visual acuity was substantially better in children (HCVA: 51.4±9.3 vs. 35.0±20.6 raw letters, p=0.001; LCVA: 22.8±14.6 vs. 13.5±16.4, p=0.028). Complete visual recovery (HCVA-logMAR 0.0) occurred in 73.3% of MOGADped and 31% MOGADadults ON eyes, while 3.3% and 31% demonstrated moderate to severe (logMAR > 0.5) visual impairment. Independent of retinal atrophy, age at ON onset significantly correlated with visual outcome. CONCLUSION: Pediatric MOGAD ON showed better visual recovery than adult MOGAD ON despite profound and almost identical neuroaxonal retinal atrophy. Age-related cortical neuroplasticity may account for the substantial discrepancy between structural changes and functional outcomes.
Assuntos
Doenças Autoimunes do Sistema Nervoso , Neurite Óptica/fisiopatologia , Retina , Transtornos da Visão/fisiopatologia , Acuidade Visual , Adolescente , Adulto , Fatores Etários , Atrofia/imunologia , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/complicações , Doenças Autoimunes do Sistema Nervoso/diagnóstico por imagem , Criança , Pré-Escolar , Estudos de Coortes , Potenciais Evocados Visuais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Glicoproteína Mielina-Oligodendrócito/imunologia , Neurite Óptica/complicações , Neurite Óptica/imunologia , Recuperação de Função Fisiológica , Retina/diagnóstico por imagem , Retina/imunologia , Retina/fisiopatologia , Degeneração Retiniana/imunologia , Degeneração Retiniana/fisiopatologia , Tomografia de Coerência Óptica , Transtornos da Visão/imunologia , Acuidade Visual/imunologiaRESUMO
OBJECTIVES: Chronic inflammatory axonal polyneuropathy (CIAP) is defined on the basis of the clinical, electrophysiological and nerve biopsy findings and therapeutic responses of 'immunotherapy responding chronic axonal polyneuropathy (IR-CAP)'. METHODS: The diagnosis of IR-CAP was made when all of three of the following mandatory criterion were met: (1) acquired, chronic progressive or relapsing symmetrical or asymmetrical polyneuropathy with duration of progression >2 months; (2) electrophysiological evidence of axonal neuropathy in at least two nerves without any evidence of 'strict criteria of demyelination'; and (3) definite responsiveness to immunotherapy. RESULTS: Thirty-three patients with IR-CAP showed similar clinical features of chronic inflammatory demyelinating polyneuropathy (CIDP) except 'motor neuropathy subtype'. High spinal fluid protein was found in 27/32 (78%) cases. 'Inflammatory axonal neuropathy' was proven in 14 (45%) of 31 sural nerve biopsies. DISCUSSIONS: IR-CAP could well be 'axonal CIDP' in view of clinical similarity, but not proven as yet. Thus, IR-CAP is best described as CIAP, a distinct entity that deserves its recognition in view of responsiveness to immunotherapy. CONCLUSION: Diagnosis of CIAP can be made by additional documentation of 'inflammation' by high spinal fluid protein or nerve biopsy in addition to the first two diagnostic criteria of IR-CAP.
Assuntos
Doenças Autoimunes do Sistema Nervoso/diagnóstico , Inflamação/diagnóstico , Polineuropatias/diagnóstico , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/diagnóstico , Adolescente , Adulto , Idoso , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/tratamento farmacológico , Doenças Autoimunes do Sistema Nervoso/fisiopatologia , Axônios/patologia , Azatioprina/uso terapêutico , Biópsia , Criança , Pré-Escolar , Doença Crônica , Ciclofosfamida/uso terapêutico , Ciclosporina/uso terapêutico , Eletromiografia , Feminino , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Inflamação/classificação , Inflamação/tratamento farmacológico , Inflamação/fisiopatologia , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/uso terapêutico , Condução Nervosa , Polineuropatias/classificação , Polineuropatias/tratamento farmacológico , Polineuropatias/fisiopatologia , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/fisiopatologia , Nervo Sural/patologia , Adulto JovemRESUMO
INTRODUCTION: In this study we evaluated a new neuropathy ultrasound protocol (NUP) for differentiating chronic immune-mediated neuropathies. METHODS: The NUP was evaluated in 110 patients with clinical presentations of chronic immune-mediated neuropathy. All patients were first evaluated clinically and electrophysiologically and divided into 4 polyneuropathy groups: (a) symmetric demyelinating; (b) symmetric axonal; (c) asymmetric demyelinating; and (d) asymmetric axonal. During step 2, the NUP was evaluated prospectively for all 4 study groups. RESULTS: Overall, the NUP led to correct classification in 42 of 49 (85.7%) patients with chronic inflammatory demyelinating polyneuropathy (CIDP), 13 of 15 (86.9%) with multifocal motor neuropathy (MMN), and 5 of 5 (100%) with multifocal-acquired demyelinating sensory and motor neuropathy (MADSAM). The NUP had >80% sensitivity and specificity in distinguishing CIDP, MMN, and MADSAM in all 4 study groups. CONCLUSIONS: The NUP is a useful addition in the differential diagnosis of chronic immune-mediated neuropathies in everyday practice. Muscle Nerve 54: 864-871, 2016.
Assuntos
Doenças Autoimunes do Sistema Nervoso/diagnóstico por imagem , Nervos Periféricos/diagnóstico por imagem , Ultrassonografia , Adulto , Idoso , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/fisiopatologia , Diagnóstico Diferencial , Eletrofisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nervos Periféricos/fisiopatologia , Sensibilidade e EspecificidadeRESUMO
Myasthenia gravis is characterized by muscle weakness and abnormal fatigability. It is an autoimmune disease caused by the presence of antibodies against components of the muscle membrane localized at the neuromuscular junction. In most cases, the autoantibodies are against the acetylcholine receptor (AChR). Recently, other targets have been described such as the MuSK protein (muscle-specific kinase) or the LRP4 (lipoprotein related protein 4). Myasthenia gravis can be classified according to the profile of the autoantibodies, the location of the affected muscles (ocular versus generalized), the age of onset of symptoms and thymic abnormalities. The disease generally begins with ocular symptoms (ptosis and/or diplopia) and extends to other muscles in 80% of cases. Other features that characterize MG include the following: variability, effort induced worsening, successive periods of exacerbation during the course of the disease, severity dependent on respiratory and swallowing impairment (if rapid worsening occurs, a myasthenic crisis is suspected), and an association with thymoma in 20% of patients and with other autoimmune diseases such as hyperthyroidism and Hashimoto's disease. The diagnosis is based on the clinical features, the benefit of the cholinesterase inhibitors, the detection of specific autoantibodies (anti-AChR, anti-MuSK or anti-LRP4), and significant decrement evidenced by electrophysiological tests. In this review, we briefly describe the history and epidemiology of the disease and the diagnostic and clinical classification. The neonatal form of myasthenia is explained, and finally we discuss the main difficulties of diagnosis.
Assuntos
Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/diagnóstico , Miastenia Gravis/classificação , Miastenia Gravis/diagnóstico , Animais , Autoanticorpos/biossíntese , Autoanticorpos/classificação , Doenças Autoimunes do Sistema Nervoso/epidemiologia , Doenças Autoimunes do Sistema Nervoso/imunologia , Doenças Fetais/classificação , Doenças Fetais/diagnóstico , Doenças Fetais/imunologia , Humanos , Recém-Nascido , Doenças do Recém-Nascido/classificação , Doenças do Recém-Nascido/diagnóstico , Doenças do Recém-Nascido/imunologia , Proteínas Relacionadas a Receptor de LDL/antagonistas & inibidores , Proteínas Relacionadas a Receptor de LDL/imunologia , Miastenia Gravis/epidemiologia , Miastenia Gravis/imunologia , Junção Neuromuscular/imunologia , Junção Neuromuscular/metabolismo , Junção Neuromuscular/patologia , Receptores Proteína Tirosina Quinases/antagonistas & inibidores , Receptores Proteína Tirosina Quinases/imunologia , Receptores Colinérgicos/imunologiaRESUMO
Modern psychiatric diagnostic systems classify neurological symptoms that cannot be explained by a physical disease or another psychiatric disorder as conversion disorder (CD) or dissociative motor disorder. It is a well-known fact that the overall rate of misdiagnosis of conversion symptoms is high. The most common presenting symptoms of misdiagnosed patients are gait and movement disturbances. Stiff-person syndrome (SPS) is a rare progressive autoimmune neurological disorder. The identification of antibodies against glutamic acid decarboxylase (GAD) in association with SPS provided an important contribution to the understanding of the pathophysiology of this syndrome. Patients may present with severe muscle rigidity and sudden contractions. Simultaneous contraction of agonist and antagonist muscles produces gait disturbance. SPS can be exacerbated by emotional stressors, and sudden auditory, visual, and tactile stimuli. Herein we present 2 patients that were referred for psychiatric assessment, because their neurological symptoms initially could not be explained by a neurological disease, and subsequently diagnosed as SPS. The aim of this case report is to draw attention to the psychiatric presentations of SPS and to emphasize the importance of complete psychiatric and neurological examination, including brain imaging and electrophysiological studies, in the differential diagnosis of CD.
Assuntos
Transtorno Conversivo/diagnóstico , Rigidez Muscular Espasmódica/diagnóstico , Adulto , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/diagnóstico , Diagnóstico Diferencial , Erros de Diagnóstico , Progressão da Doença , Feminino , Humanos , Transtornos Somatoformes/classificação , Transtornos Somatoformes/diagnóstico , Rigidez Muscular Espasmódica/fisiopatologiaRESUMO
Streptococcal infection in children is usually benign and self-limited. In a small percentage of children, prominent neurologic and/or psychiatric sequelae can occur. Sydenham chorea is the best defined and best recognized. PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection) is a well-defined syndrome in which tics (motor and/or vocal) and/or obsessive-compulsive disorder consistently exacerbate in temporal correlation to a group A beta-hemolytic streptococcal infection. PANDAS constitutes a subset of children with tics, Tourette syndrome, and obsessive-compulsive disorder. In addition to strictly defined PANDAS, we and others have recognized several PANDAS variants, including adult-onset variant, a dystonic variant, a myoclonic variant, and a "chronic" PANDAS variant. The nosology and classification of these entities are rapidly evolving. The recognition that some pediatric neurobehavioral syndromes have infectious and/or immunologic triggers points to important new avenues of disease treatment. In this review, we summarize this complex and rapidly evolving area of clinical research.
Assuntos
Doenças Autoimunes do Sistema Nervoso/diagnóstico , Coreia/diagnóstico , Transtorno Obsessivo-Compulsivo/diagnóstico , Infecções Estreptocócicas/complicações , Streptococcus pyogenes , Transtornos de Tique/diagnóstico , Adolescente , Adulto , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/imunologia , Doenças Autoimunes do Sistema Nervoso/microbiologia , Criança , Pré-Escolar , Coreia/imunologia , Coreia/microbiologia , Humanos , Lactente , Transtorno Obsessivo-Compulsivo/imunologia , Transtorno Obsessivo-Compulsivo/microbiologia , Polissacarídeos Bacterianos/imunologia , Infecções Estreptocócicas/imunologia , Síndrome , Transtornos de Tique/imunologia , Transtornos de Tique/microbiologiaRESUMO
The usefulness of functional scales has become clear in the past few years, to evaluate patients with dysimmune peripheral neuropathies. Functional scales which measure the real impact of the disease process in our patients will probably be increasingly used in future therapeutic trials. By contrast with neurological disorders leading to pure motor involvement, peripheral neuropathies are difficult to evaluate, due to their clinical polymorphism. However, efforts have been made in the past ten years in order to validate functional scales that may be routinely used by neurologists for dysimmune neuropathies. New scales will probably arise in the next few years, to be used in neuropathies from other causes. These scales will have to be strictly validated to be used in the daily medical practice.
Assuntos
Doenças Autoimunes do Sistema Nervoso/classificação , Doenças do Sistema Nervoso Periférico/classificação , Índice de Gravidade de Doença , Doenças Autoimunes do Sistema Nervoso/diagnóstico , Doenças Autoimunes do Sistema Nervoso/fisiopatologia , Ensaios Clínicos como Assunto/métodos , Avaliação da Deficiência , Humanos , Doenças do Sistema Nervoso Periférico/diagnóstico , Doenças do Sistema Nervoso Periférico/fisiopatologia , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
The Chronic Dysimmune neuropathies (CDN) are a clinically heterogeneous group of polyneuropathies united by their presumed immune mediated aetiology. At present such neuropathies are classified as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) and the Neuropathies in association with serum Paraproteins (Paraproteinaemic Neuropathies). This classification fails to recognise other distinctive syndromes and is limited by heterogeneity within, and overlap between, subgroups. We have refined this clinical subclassification by a review of a consecutive series of 102 unselected patients with CDN referred to a single neurologist. We recognise 6 clinical subtypes of CDN: one sensory ataxic group; three motor-sensory subgroups (chronic motor sensory demyelinating neuropathy, subacute motor sensory demyelinating neuropathy and a multifocal motor sensory neuropathy); and two pure motor subgroups (symmetric pure motor demyelinating neuropathy and multifocal motor neuropathy). This subclassification allows distinct syndromes to be recognised and helps resolve problems of heterogeneity and overlap. Distinction between these subgroups is of immediate practical relevance to patient management. Although steroids are beneficial for most of the subgroups, this is not so for both of the pure motor syndromes which should be treated with intravenous immunoglobulin. Patients with chronic development of Motor Sensory Demyelinating Neuropathy respond less well to steroids than those with a subacute onset. An association was found between elderly patients with Subacute Motor Sensory Demyelinating Neuropathy and carcinomas. Within any clinical subgroup patients behave similarly regardless of the presence of associated paraproteins or nerve specific antibodies.
Assuntos
Doenças Autoimunes do Sistema Nervoso/classificação , Adolescente , Adulto , Idoso , Alergia e Imunologia , Ataxia/etiologia , Doenças Autoimunes do Sistema Nervoso/diagnóstico , Doenças Autoimunes do Sistema Nervoso/fisiopatologia , Doenças Autoimunes do Sistema Nervoso/terapia , Líquido Cefalorraquidiano/metabolismo , Criança , Doença Crônica , Doenças dos Nervos Cranianos/classificação , Doenças dos Nervos Cranianos/diagnóstico , Doenças dos Nervos Cranianos/fisiopatologia , Doenças dos Nervos Cranianos/terapia , Doenças Desmielinizantes/classificação , Doenças Desmielinizantes/diagnóstico , Doenças Desmielinizantes/fisiopatologia , Doenças Desmielinizantes/terapia , Eletrodiagnóstico/métodos , Feminino , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Masculino , Pessoa de Meia-Idade , Doença dos Neurônios Motores/classificação , Doença dos Neurônios Motores/fisiopatologia , Doença dos Neurônios Motores/terapia , Neoplasias , Condução Nervosa/fisiologia , Exame Neurológico/métodos , Troca Plasmática/métodos , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/diagnóstico , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/fisiopatologia , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/terapia , Estudos Retrospectivos , Esteroides/uso terapêutico , Nervo Sural/patologia , Fatores de Tempo , Tremor/etiologiaRESUMO
An autoimmune mechanism for ADEM and MS can be supported by the similar patterns of pathologic changes seen in both diseases with the animal model EAE induced by inoculating animals with nervous tissue and the occurrence of ADEM in patients exposed to nervous tissue during vaccination. Whereas there are no universally agreed-upon criteria for the diagnosis of ADEM, a combination of prodromal illness or preceding vaccination, MRI signs of demyelination, and an acute presentation of neurologic symptoms are the triad most commonly looked for in making the diagnosis of ADEM. An ever-increasing number of infections and vaccinations (nonspecific URIs being most common) has been associated with ADEM. Fever and encephalopathy are seen frequently at presentation. Seizures also are common, as are cranial nerve abnormalities and motor symptoms. A mild pleocytosis or protein elevation is found in the majority of patients with ADEM. Intrathecal IgG synthesis and oligoclonal bands are relatively infrequent but should not be considered inconsistent with the diagnosis of ADEM. White matter changes on T2 in a bilateral although asymmetric distribution with relative sparing of the periventricular region with or without deep gray matter involvement is consistent and to some a requirement for the diagnosis. Low-dose steroids have no beneficial effect in the treatment of ADEM and may be contraindicated. High-dose steroids may have a beneficial effect, particularly in more prolonged illnesses, although the evidence is primarily anecdotal. If steroids are used to improve morbidity, 30 mg/kg/d of methylprednisolone for three to five days is the dose with a six-week taper to reduce the risk of recurrence. The prodromal infection may be a major factor in the ultimate mortality and morbidity of the disease. The current mortality of ADEM is quite low. Whether or not this is an effect of different triggering agents or changes in medical care cannot be determined. In larger series of patients with ADEM, 10% to 20% of children experience some sort of recurrence with the majority occurring in the initial one to two months after the first event. This is sometimes associated with steroid withdrawal. A second group of children have a late second recurrence that clinically may not be MS but a recurrence of ADEM, although longer follow-up may change that assessment. Two months should be allowed before a second relapse is considered a manifestation of MS, whereas a second attack also may occur years after an initial attack of ADEM and still be consistent with ADEM recurrence. MS does occur during childhood, with the youngest children at the least risk, and risk increasing with age. The criteria of Poser et al can be used to diagnose MS in childhood [40]. The presentation of MS in childhood is most often sensory, motor, and brainstem signs and symptoms. A relapsing-remitting course is most common with a first relapse occurring in the year after presentation. MRI findings in MS typically show periventricular changes. Oligoclonal bands and CSF IgG synthesis are found in the majority. Treatments of childhood MS have not been studied adequately, but, when treatments studied in adults are used in children, they are well tolerated. Efficacy has not been shown. The long-term outcome of MS in childhood can be either severe or benign with no clear consensus that childhood MS is either a less or more severe disease than the adult form. ATM and ON treatments and outcomes are particularly difficult to evaluate because of the heterogeneity of populations included in case series and the small numbers reported. Steroids are used with anecdotal reports of their superiority to nontreatment. Outcome in ATM often can be poor, whereas in ON it rarely is. A multinational collaborative effort to study and collect the large numbers necessary to address the important questions in these childhood autoimmune disorders would be of great benefit and the only way likely to demonstrate good evidenced-based medicine practiced in this field.
Assuntos
Anti-Inflamatórios/uso terapêutico , Doenças Autoimunes do Sistema Nervoso/patologia , Anti-Inflamatórios/administração & dosagem , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/tratamento farmacológico , Biópsia , Criança , Esquema de Medicação , Humanos , Imageamento por Ressonância Magnética , RecidivaRESUMO
The immune-mediated diseases of the central nervous system (CNS) cover a wide range of clinical manifestations. Over the last years, considerable efforts have been made to establish a nosologic concept based upon distinctive pathophysiological characteristics of the single diseases. We describe the historically defined entities of immune-mediated diseases that primarily, but not exclusively, are affecting myelin structures. These include very rare entities as Schilder's, Balo's and Marburg's disease or the chronic and relapsing types of optic neuritis, for which evidence based paradigms still are virtually missing. In other, slightly more frequent diseases as neuromyelitis optica (NMO), advances in the concepts of specific biological features have been achieved and are beginning to transform into changes in clinical concepts. Acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) are by far the most frequent entities in this group and thus the only ones for which extensive empirical data on disease biology and evidence based clinical management strategies exist by now. For the most important entities, clinical features and therapeutic approaches are reviewed on the basis of current evidence. The results of basic science studies are assessed for their implications in nosological classification.
Assuntos
Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/imunologia , Animais , Doenças Autoimunes do Sistema Nervoso/diagnóstico , Sistema Nervoso Central/imunologia , Encefalomielite Aguda Disseminada/classificação , Encefalomielite Aguda Disseminada/diagnóstico , Encefalomielite Aguda Disseminada/imunologia , Medicina Baseada em Evidências , Humanos , Esclerose Múltipla/classificação , Esclerose Múltipla/diagnóstico , Esclerose Múltipla/imunologia , Mielite Transversa/classificação , Mielite Transversa/diagnóstico , Mielite Transversa/imunologia , Neuromielite Óptica/classificação , Neuromielite Óptica/diagnóstico , Neuromielite Óptica/imunologia , Neurite Óptica/classificação , Neurite Óptica/diagnóstico , Neurite Óptica/imunologia , RecidivaRESUMO
Anti-ganglioside complexes (GSCs) IgG antibodies have been reported in patients with Guillain-Barré (GBS) or Fisher syndrome but little is known on their presence in multifocal motor neuropathy (MMN) or other chronic immune-mediated neuropathies. We examined 24 patients with MMN, 34 with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 23 with neuropathy associated with IgM monoclonal gammopathy (PN+IgM), 13 with GBS, 34 with motor neuron disease (MND), 24 with other neuropathies and 20 normal subjects. Patients' sera were tested by ELISA for IgM reactivity to GM1, GM2, GD1a, GD1b and GT1b and with GSCs made by any combination of two of these gangliosides. In all GM1 positive patients with MMN (11), PN+IgM (1), CIDP (1) and POEMS (1), binding to GM1 was abolished or consistently reduced when tested in GSCs also containing GD1a or other gangliosides. This only occurred in one of the three GM1 positive MND patients. In a patient with PN-IgM and anti-GM2 and GD1a IgM, both reactivities were reduced when tested in GSCs also containing GM1. New reactivities were found in a patient with CIDP and anti-GD1b IgM who presented an additional reactivity to GT1b/GM1 and GT1b/GM2 GSCs, and in one with PN-IgM who had reactivity to GM2/GD1b but not to individual gangliosides. Testing for IgM antibodies to GSCs rarely permitted to identify new reactivities in chronic immune neuropathies. IgM binding to gangliosides was however often modified in GSCs suggesting that these reactivities may be affected by contiguous gangliosides possibly influencing their pathogenicity.
Assuntos
Doenças Autoimunes do Sistema Nervoso/imunologia , Gangliosídeos/imunologia , Imunoglobulina M/imunologia , Doença dos Neurônios Motores/imunologia , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/complicações , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Gangliosídeos/classificação , Humanos , Imunoglobulina M/sangue , Masculino , Doença dos Neurônios Motores/complicações , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/imunologiaRESUMO
The acetylcholine receptor ganglionic (G-AchR) antibody is a very specific serologic test for autoimmune autonomic ganglionopathy. The spectrum of autoimmune (or presumed to be autoimmune) autonomic disorders, however, is quite broad and positivity to this antibody has been reported in a variety of other conditions, albeit infrequent and with low titer. This review describes the autonomic neuropathies most frequently encountered in clinical practice in which an autoimmune etiology is suspected. They include a chronic form (pure autonomic failure) and limited autonomic neuropathies with predominant involvement of one neurotransmitter type (i.e., cholinergic vs. adrenergic) or one system (such as the gastrointestinal system) or a distal small fiber dysfunction. In each of these conditions, occasional positivity to the G-AchR antibody has been found, but the pathogenetic significance of such finding is still uncertain. Other antigens and antibodies yet to be identified are more likely to be responsible in these disorders.
Assuntos
Autoanticorpos/imunologia , Autoantígenos/imunologia , Doenças Autoimunes do Sistema Nervoso/imunologia , Doenças do Sistema Nervoso Autônomo/imunologia , Gânglios Autônomos/imunologia , Receptores Nicotínicos/imunologia , Adulto , Idoso , Doenças Autoimunes do Sistema Nervoso/classificação , Doenças Autoimunes do Sistema Nervoso/etiologia , Doenças do Sistema Nervoso Autônomo/classificação , Doenças do Sistema Nervoso Autônomo/etiologia , Doença Crônica , Feminino , Gânglios Autônomos/química , Humanos , Hipo-Hidrose/etiologia , Pseudo-Obstrução Intestinal/imunologia , Masculino , Síndrome da Taquicardia Postural Ortostática/imunologia , Insuficiência Autonômica Pura/etiologia , Insuficiência Autonômica Pura/imunologia , Síndrome de Shy-Drager/etiologia , Síndrome de Shy-Drager/imunologia , Viroses/complicações , Adulto JovemRESUMO
BACKGROUND: Immune treatments are recommended for patients with Guillain-Barré syndrome (GBS) who cannot walk independently, but a considerable number of GBS patients are in the progressive phase at the first examination. OBJECTIVE: To investigate whether progression patterns differ in demyelinating and axonal subtypes of GBS. METHODS: Clinical, laboratory, and electrophysiologic data on 131 consecutive patients with GBS were reviewed. Patients were classified as having acute inflammatory demyelinating polyneuropathy (AIDP) or acute motor axonal neuropathy (AMAN) based on electrodiagnostic criteria. RESULTS: Forty-one patients had AIDP, 62 AMAN, and 28 were unclassified. Age, sex, and Hughes Functional Grading Scale score at the first medical examination did not differ for the AIDP and AMAN patients. Mean periods between neurologic onset and first examination (5.3 vs 4.2 days; p = 0.01) and neurologic onset and nadir (18.0 vs 11.5 days; p = 0.001) were longer for the AIDP group. In the subgroup of those with mild disability (able to walk independently at the first neurologic examination), 88% of the AMAN patients had reached the nadir, whereas 65% of the AIDP patients had reached it. The remaining 35% progressed to it over the next 1 to 2 weeks and were unable to walk at nadir. CONCLUSIONS: The patterns and speeds of progression differ in AMAN and AIDP, AMAN having a rapid progression and an early nadir. AIDP patients frequently have a significantly long progression after the first examination; therefore, they need to be carefully monitored.